The Flow Cytometry/Optical Morphology Shared Resource of the Mayo Clinic Cancer Center (MCCC) combines two complimentary technologies - flow cytometry and optical morphology. Flow cytometry is used for high-speed analysis of particles (usually cell populations) in liquid suspension. Optical Morphology is used for image-based analysis of structure and localization within cells or tissue. The resource provides sophisticated instrumentation including bench-top analytical flow cytometers and high-speed cell sorters, confocal microscopes and other light microscope based imaging systems. The facility is staffed with experienced personnel to assist with training, customized image analysis macro programming, data management and data interpretation. The facility is also provided to advance the knowledge and capabilities of these and related technologies. Resource personnel perform all sorting applications. Resource personnel also run the majority of analytical flow cytometry samples. However, users have the option of running their own samples on the analytical instruments. For users that choose this option, instrument training is provided on a one-on-one basis. Training is also provided for all optical morphology instrumentation. Resource personnel are available for assistance with troubleshooting, maintenance, data interpretation, and experimental design. The services of the Shared Resource appeal to a broad base of Cancer Center basic science programs. A very large number of MCCC members utilize the resource as a critical component in their research applications. The availability of instrumentation and expertise contributes to the measurement and understanding of apoptosis and cell cycle regulation, three-dimensional localization of proteins, kinetic responses involving intracellular ions and many other important events necessary for the understanding and regulation of cancer related processes. Adaptations to equipment and procedures allow for flexibility in providing services to MCCC members involved in utilizing cytometric bead array assays, single cell sorting and multi-spectral image acquisition.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-33
Application #
7414498
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2007-03-01
Budget End
2008-02-29
Support Year
33
Fiscal Year
2007
Total Cost
$210,734
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8
O'Mara, Tracy A; Glubb, Dylan M; Amant, Frederic et al. (2018) Identification of nine new susceptibility loci for endometrial cancer. Nat Commun 9:3166
Wallace, Sumer K; Halverson, Jessica W; Jankowski, Christopher J et al. (2018) Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy. Obstet Gynecol 131:891-898
Shrestha, Shikshya; Zhang, Cheng; Jerde, Calvin R et al. (2018) Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. Clin Pharmacol Ther 104:709-718
Hu, G; Dasari, S; Asmann, Y W et al. (2018) Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 32:565-569
Geller, James I; Fox, Elizabeth; Turpin, Brian K et al. (2018) A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer 124:4548-4555
Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398
Oishi, Naoki; Brody, Garry S; Ketterling, Rhett P et al. (2018) Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 132:544-547
DuBois, Steven G; Mosse, Yael P; Fox, Elizabeth et al. (2018) Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res 24:6142-6149
Farber, Benjamin A; Lalazar, Gadi; Simon, Elana P et al. (2018) Non coding RNA analysis in fibrolamellar hepatocellular carcinoma. Oncotarget 9:10211-10227

Showing the most recent 10 out of 1129 publications